B
3.18
-0.04 (-1.24%)
| Penutupan Terdahulu | 3.22 |
| Buka | 3.31 |
| Jumlah Dagangan | 64,856 |
| Purata Dagangan (3B) | 236,995 |
| Modal Pasaran | 114,003,000 |
| Harga / Jualan (P/S) | 109.70 |
| Harga / Buku (P/B) | 0.510 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 20 Mar 2025 |
| Margin Operasi (TTM) | -1,133.43% |
| EPS Cair (TTM) | -1.98 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.29% |
| Nisbah Semasa (MRQ) | 13.68 |
| Aliran Tunai Operasi (OCF TTM) | -53.21 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -34.85 M |
| Pulangan Atas Aset (ROA TTM) | -19.54% |
| Pulangan Atas Ekuiti (ROE TTM) | -30.20% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menurun | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menurun | Bercampur | |
| Stok | BioAge Labs, Inc. | Menurun | - |
AISkor Stockmoo
0.5
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.50 |
|
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| % Dimiliki oleh Orang Dalam | 3.63% |
| % Dimiliki oleh Institusi | 66.65% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Redpoint Management, Llc | 31 Dec 2024 | 383,255 |
| Julat 52 Minggu | ||
| Median | 5.00 (57.23%) | |
| Jumlah | 1 Pegang | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citigroup | 24 Mar 2025 | 5.00 (57.23%) | Pegang | 4.54 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 17 Jun 2025 | Pengumuman | BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank |
| 03 Jun 2025 | Pengumuman | BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates |
| 29 May 2025 | Pengumuman | BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic |
| 27 May 2025 | Pengumuman | BioAge Labs to Present at Upcoming Investor Conferences |
| 06 May 2025 | Pengumuman | BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates |
| 20 Mar 2025 | Pengumuman | BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024 |
| 17 Mar 2025 | Pengumuman | BioArctic receives Orphan Drug Designation for exidavnemab the US |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |